A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

PHASE2CompletedINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

September 26, 2024

Study Completion Date

March 19, 2025

Conditions

Endometriosis

Interventions

DRUG

HMI-115

HMI-115 is human monoclonal antibody

DRUG

Placebo

Trial Locations (5)

Tidewater Clinical Research/TPW, Norfolk

Physicians' Research Options, LLC- Corner Canyon Clinic, Draper

Peking Union Medical College Hospital, Beijing

Instytut Matki i Dziecka, Warsaw

Specjalistyczna Poradnia Ginekologiczna Gabinet Ginekologiczny Dr med. Janusza Tomaszewskiego, Bialystok

All Listed Sponsors

lead

Hope Medicine (Nanjing) Co., Ltd

INDUSTRY

NCT05101317 - A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain | Biotech Hunter | Biotech Hunter